pharma · Uveal Melanoma · HLA-A2 negative metastatic uveal melanoma · IDYA
IDEAYA Biosciences
IDEAYA Biosciences is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker IDYA. Primary therapeutic focus areas include Uveal Melanoma, HLA-A2 negative metastatic uveal melanom
5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US HQ
2015 Founded
248 Employees
Public company Type
IDYA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5000 Shoreline Ct, Suite 300, South San Francisco, California 94080, US
- Founded
- 2015
- Employees
- 248
- Programs
- 14
- Drugs
- 12
- Patents
- 12
IDE-161
Phase 1 · small molecule · Advanced or Metastatic Solid Tumors
IDE-161 for Advanced or Metastatic Solid Tumors is a Phase 1 program (small_molecule) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).
Internal code IDE161-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IDEAYA Biosciences
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Advanced or Metastatic Solid Tumors
- Status
- active
- Trials
- 1